ASH Meeting on Lymphoma Biology
The 2020 ASH Meeting on Lymphoma Biology has been canceled. ASH has decided to cancel the meeting as a precautionary measure in response to the COVID-19 outbreak in the U.S. and worldwide. The health and safety of our meeting attendees is ASH’s top priority.
ASH encourages those who had planned to submit abstracts for this meeting to instead submit for consideration to ASH’s Annual Meeting and Exposition, the premier event in malignant and non-malignant hematology. The abstract submission site will open on June 4, 2020.
The ASH Meeting on Lymphoma Biology was established in 2014 to address an unmet need in the lymphoma community: to serve as the only U.S.-based forum specifically focused on basic and translational science relevant to lymphoma and chronic lymphocytic leukemia. The central goal of the meeting is to bring together experts from around the world to discuss the latest lymphoma fundamental science, address current challenges in the field, establish the highest priorities for investigation, and develop novel therapeutics.
This ACCME-accredited meeting consists of didactic sessions, abstract presentations, interactive workshops, and panel discussions. One important aspect of the meeting is Continuing Conversations, which are informal, interactive discussions designed for meeting attendees to address issues relevant to the lymphoma community. View the 2020 program.
Through participation in this meeting, you will be able to:
- Discuss cutting-edge lymphoma research in a relaxed, informal setting.
- Present and hear newest unpublished results.
- Learn about current challenges in the field and the next steps to address those challenges.
- Establish collaborations with leading experts in academia and industry.
- Discuss how collaborative efforts can help accelerate the development of new therapeutic strategies.
- Interact with attendees and build your professional network.
- Earn CME and MOC credits.
The previous meetings (in 2014, 2016, and 2018) attracted more than 240 professional attendees from 24 countries, including more 65 trainees, junior researchers, and medical students.
Who Should Attend?
- Laboratory-based investigators
- Translational investigators
- Junior faculty and trainees
- Life sciences and biopharmaceutical industry
- Policy-makers and regulatory scientists
- Practitioners and other health professionals interested in lymphoma science
- Laura Pasqualucci, MD
- Elias Campo, MD, PhD
University of Barcelona
- Ralf Küppers, PhD
University of Duisburg-Essen
Steering Committee Members
- Laura Pasqualucci, MD, Columbia University [Co-chair]
- Elias Campo, MD, PhD, University of Barcelona [Co-chair]
- Ralf Küppers, PhD, University of Duisburg-Essen [Co-chair]
- Catherine Bollard, MD, MbChB, Children’s National Medical Center
- Wing C. (John) Chan, MD, City of Hope Medical Center
- Dan Landau, MD, PhD, New York City Genome Center
- Ronald Levy, MD, Stanford University
- Bertrand Nadel, PhD, French National Institute of Health and Medical Research
- Margaret Shipp, MD, Dana Farber Cancer Institute
- Louis Staudt, MD, PhD, National Cancer Institute
- Christian Steidl, MD, British Columbia Cancer Agency
- Karin Tarte, PharmD, PhD, University of Rennes
- Margot Thome-Miazza, PhD, University of Lausanne
Explore the Meeting on Lymphoma Biology
- Schedule and Program
- Session Descriptions
- Hotel Information
- Abstract Review Categories
- CME and MOC
- Commercial Support
Please submit all general inquiries to [email protected]. For information about sponsoring and/or exhibiting at MLB, contact SPARGO, Inc. at 800-564-4220, 703-631-6200, or [email protected].
- Blood Review Series - Biological Insights into Lymphoid Tumors
Read a series of four reviews that highlight recent insights into a range of lymphoid tumors in an era of explosively increasing knowledge of genetics, epigenetics, and tumor-environment interactions and clinical testing of precision drug targeting.
- Roadmap for Discovery and Translation in Lymphoma
Review priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma.